2-aminopropanoic acid [1-(4-chlorophenyl)-2-methylpropan-2-yl] ester is an alpha-amino acid ester.
Alaproclate was developed as one of the first selective serotonin reuptake inhibitor (SSRI) antidepressants by Astra AB (now AstraZeneca) in the 1970s. Development was discontinued due to concerns over hepatotoxicity observed in animal studies. Alaproclate has also been found to act as a non-competitive NMDA receptor antagonist although without discriminative stimulus properties similar to phencyclidine.
ALAPROCLATE is a small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
specific 5-hydroxytryptamine uptake inhibitors; RN given refers to (DL)-isome

Methods and Technical Details

The synthesis of alaproclate involves several key steps:

1. Grignard Reaction: Methylmagnesium iodide, a Grignard reagent, reacts with methyl 4-chlorophenylacetate to produce a tertiary alcohol, specifically 1-(4-chlorophenyl)-2-methyl-2-propanol.
2. Acylation: The tertiary alcohol is then acylated using 2-bromopropionyl bromide to form an ester.
3. Amination: Finally, the ester undergoes treatment with ammonia to yield alaproclate.

These synthetic routes highlight the importance of controlling reaction conditions such as temperature and purity of reagents to achieve high yields and product consistency.

Structure and Data

Alaproclate’s molecular structure features a 4-chlorophenyl group attached to an amino acid ester component. The compound’s structural formula can be represented as follows:

• Chemical Formula: C13H18ClNO2C13​H18​ClNO2​
• Molar Mass: Approximately 255.74 g/mol
• IUPAC Name: (S)-1-[4-(Chlorophenyl)]-2-methyl-2-propanamine

The structural representation emphasizes the presence of functional groups that contribute to its pharmacological effects, particularly its ability to inhibit serotonin reuptake  .

Reactions and Technical Details

Alaproclate can participate in various chemical reactions:

1. Oxidation: Alaproclate may undergo oxidation under specific conditions, although detailed pathways are not extensively documented. Common oxidizing agents include potassium permanganate or chromium trioxide.
2. Reduction: Reduction reactions can modify its functional groups, potentially altering pharmacological properties. Reducing agents such as lithium aluminum hydride or sodium borohydride are typically employed.
3. Substitution: The compound can also undergo substitution reactions involving its aromatic ring and ester group, utilizing halogenating agents or nucleophiles depending on the desired outcome .

These reactions are significant for understanding alaproclate’s chemical behavior and potential modifications for therapeutic applications.

Alaproclate primarily exerts its effects by inhibiting the reuptake of serotonin in the synaptic cleft. This mechanism increases serotonin availability, which is critical for mood regulation. Additionally, alaproclate has been identified as a non-competitive antagonist at NMDA receptors, which may contribute to its neuropharmacological effects .

Research indicates that while it shares similarities with other SSRIs in terms of serotonin uptake inhibition, it possesses unique properties that differentiate it from more widely used SSRIs like fluoxetine .

Physical and Chemical Properties

• Appearance: Alaproclate is typically presented as a white crystalline powder.
• Solubility: It is soluble in organic solvents but has limited solubility in water.
• Stability: The compound is stable under normal storage conditions but may degrade under extreme pH or temperature conditions.

These properties are essential for understanding how alaproclate behaves in biological systems and during formulation for therapeutic use .

Scientific Uses

Although alaproclate’s development as an antidepressant was discontinued due to safety concerns, it has been studied for various scientific applications:

• Pharmacology: Alaproclate serves as a model compound for studying SSRI mechanisms and structure-activity relationships.
• Neuropharmacology: Its unique profile as an NMDA receptor antagonist opens avenues for research into cognitive disorders and mood regulation.
• Comparative Studies: Research comparing alaproclate with other SSRIs provides insights into drug efficacy and safety profiles, contributing to the development of new antidepressants  .

Historical Context and Discovery of Alaproclate

Alaproclate (developmental code name GEA-654) was synthesized in the 1970s by Swedish pharmaceutical company Astra AB (now AstraZeneca) as part of a program to develop novel antidepressants targeting monoamine systems. Its discovery emerged from systematic structural modifications of phenethyl alcohol esters, specifically designed to enhance selectivity for serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition. Lindberg et al. first described the compound in 1978, detailing a synthesis pathway involving:

• Grignard reaction: Methylmagnesium iodide with methyl 4-chlorophenylacetate yielded the tertiary alcohol 1-(4-chlorophenyl)-2-methyl-2-propanol [1]
• Esterification: Subsequent acylation with 2-bromopropionyl bromide formed a brominated ester intermediate
• Ammoniation: Treatment with ammonia produced racemic alaproclate [1] [10]

Table 1: Key Chemical Properties of Alaproclate

Property	Value
IUPAC Name	1-(4-Chlorophenyl)-2-methylpropan-2-yl 2-aminopropanoate
Molecular Formula	C₁₃H₁₈ClNO₂
Molecular Weight	255.74 g/mol
CAS Registry	60719-82-6
Stereochemistry	Racemic mixture

Alaproclate represented a structural departure from tricyclic antidepressants (TCAs), featuring an α-amino ester moiety linked to a chlorinated phenethyl backbone. This design aimed to minimize affinity for histaminergic, cholinergic, and adrenergic receptors—common sources of TCA side effects [8] [10].

Pharmacological Classification and Early Therapeutic Intent

Alaproclate was pharmacologically characterized as a selective serotonin reuptake inhibitor (SSRI) with minimal activity on other neurotransmitter systems:

Receptor Selectivity Profile

• High selectivity: Potent inhibition of serotonin transporter (SERT; IC₅₀ ~0.3 µM) [3] [8]
• Negligible affinity: No significant binding to histamine H₁, α₁/α₂-adrenergic, dopamine D₂, or 5-HT receptors in vitro [8] [10]
• Muscarinic receptor sparing: Unlike TCAs, showed no anticholinergic effects in functional assays [10]

Table 2: Receptor Binding Profile of Alaproclate vs. Reference Compounds

Receptor Target	Alaproclate Affinity	Imipramine Affinity	Clomipramine Affinity
Serotonin Transporter	High (Kᵢ < 1 µM)	High	High
Norepinephrine Transporter	Very Low	High	High
Muscarinic Cholinergic	Undetectable	High	Moderate
α₁-Adrenergic	Undetectable	Moderate	Low

Regional Selectivity in the CNS

Alaproclate exhibited region-specific uptake inhibition in rodent brain tissues when assessed using the H 75/12 method:

• Hippocampus (most sensitive)
• Hypothalamus
• Striatum
• Cerebral cortex
• Spinal cord (least sensitive) [10]

This gradient suggested potential therapeutic advantages for disorders involving limbic system dysregulation. Early clinical development targeted major depressive disorder and senile dementia, with Phase 2 trials conducted in Belgium, Sweden, and the UK during the early 1980s [5]. Its dual potential was attributed to:

• Serotonergic modulation of mood circuits
• Cognitive effects observed in animal models of memory impairment [10]

Role in the Evolution of Serotonergic Antidepressants

Alaproclate was among the first-generation SSRIs developed alongside zimelidine and indalpine, predating clinically successful agents like fluoxetine (Prozac) by nearly a decade [1] [6]. Its development marked pivotal shifts in antidepressant research:

Conceptual Innovations

• Specificity over multiplicity: Rejected the “shotgun” pharmacology of TCAs in favor of targeted SERT inhibition [6] [10]
• Chemical novelty: Demonstrated antidepressant efficacy without tricyclic scaffolds, expanding medicinal chemistry options [1]
• Neuroanatomical precision: Regional selectivity hinted at pathway-specific modulation, contrasting global monoamine depletion theories [10]

Limitations and Legacy

Despite promising pharmacology, development was discontinued in the 1980s due to:

• Hepatotoxicity signals: Rodent studies revealed liver complications not observed in earlier assessments [1] [9]
• Competitive landscape: Emergence of zimelidine (withdrawn for Guillain-Barré syndrome) and fluoxetine [6]

Nevertheless, alaproclate’s unique properties informed subsequent developments:

• NMDA receptor modulation: Later discovered to act as a non-competitive NMDA receptor antagonist without phencyclidine-like discriminative stimulus properties [1] [2]
• Structural templates: Its α-aminopropanoate ester motif influenced later neuroprotective agent design
• Dual-mechanism candidates: Pioneered exploration of compounds targeting both monoamine uptake and glutamate receptors [2]

Alaproclate’s trajectory exemplifies the “proof-of-concept” phase of SSRI development, validating SERT inhibition as a therapeutically viable strategy while underscoring the translational challenges between preclinical models and clinical safety [6] [10]. Its biochemical insights remain embedded in contemporary antidepressant design, particularly agents targeting treatment-resistant depression through glutamatergic-serotonergic interactions.